HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS		QUICK SEARCH:   [advanced] Author: Keyword(s): Year:  Vol:  Page:

This Article Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Wilson, R. Articles by Thomson, J. A. Search for Related Content PubMed PubMed Citation Articles by Wilson, R. Articles by Thomson, J. A.

Relapse of Graves' Disease After Medical Therapy: Predictive Value of Thyroidal Technetium-99m Uptake and Serum Thyroid Stimulating Hormone Receptor Antibody Levels

University Department of Medicine, Royal Infirmary
West of Scotland Health Boards Department of Clinical Physics, Glasgow, Scotland

Correspondence: For reprints contact: J. H. McKillop, MB, PhD, University Dept. of Medicine, Royal Infirmary, 10 Alexandra Parade, Glasgow G31 2 ER.

ABSTRACT

In 49 patients with Graves' disease, the 20-min thyroidal uptake of ^99mTc and serum levels of thyroid stimulating hormone (TSH) receptor antibody were estimated at presentation and at intervals during a 1-yr course of carbimazole and triiodothyronine. In the 12 mo after cessation of therapy, 29 patients developed recurrent thyrotoxicosis. Thyroidal ^99mTc uptake had a poor predictive value for recurrence of thyrotoxicosis, both at presentation and during therapy. A very high level of TSH receptor antibody was present in seven patients at presentation, all of whom relapsed on withdrawing therapy. An abnormal value of TSH receptor antibody at the end of the course of medical therapy was present in 24/29 (83%) patients who relapsed and in 1/20 (5%) patients who remained euthyroid 1 yr after stopping antithyroid drugs.

FOOTNOTES

^* Present address: Dept. of Medicine, Royal Infirmary, Aberdeen, Scotland.

This article has been cited by other articles:

				T. F. Davies Thyroid-Stimulating Antibodies Predict Hyperthyroidisma J. Clin. Endocrinol. Metab., November 1, 1998; 83(11): 3777 - 3781. [Full Text]

				E. Roti, L. E. Braverman, and L. J. DeGroot TSH Receptor Antibody Measurement in the Diagnosis and Management of Graves' Disease Is Rarely Necessaryb J. Clin. Endocrinol. Metab., November 1, 1998; 83(11): 3781 - 3784. [Full Text]